Neurexins are neuronal cell surface proteins with hundreds of isoforms generated by alternative splicing. Here we describe neuroligin 1, a neuronal cell surface protein that is enriched in synaptic plasma membranes and acts as a splice site-specific ligand for p-neurexins. Neuroligin 1 binds to I~-neurexins only if they lack an insert in the alternatively spliced sequence of the G domain, but not if they contain an insert. The extracellular sequence of neuroligin 1 is composed of a catalytically inactive esterase domain homologous to acetylcholinesterase. In situ hybridization reveals that alternative splicing of neurexins at the site recognized by neuroligin 1 is highly regulated. These findings support a model whereby alternative splicing of neurexins creates a family of cell surface receptors that confers interactive specificity onto their resident neurons.
Introduction
some of the splice sites may have more than 10 variants. As a result, the total number of neurexins in brain probably exceeds 2000 forms (UIIrich et al., 1995) . The variable sequences of the neurexins render them among the most polymorphic proteins known.
The structures of the neurexins suggest a possible function as cell surface receptors. Neurexins contain epidermal growth factor-like sequences and domains homologous to the G domain repeats of laminin A, indicating a function in cell-cell interactions. A 29 kDa protein copurifying with neurexin I~ in the ~-Iatrotoxin receptor has a structure suggestive of a soluble ligand for neurexins (Ao G. Petrenko and T. C. S., unpublished data). Putative ligands for neurexins could interact with all neurexins or with subsets of neurexins characterized by a specific pattern of alternative splicing. In the latter instance, alternative splicing would regulate the ligand specificity of each neurexin, implying the existence of a large number of different ligands.
Here we report the identification of a novel neuronal cell surface protein that binds to all three 13-neurexins but not to a-neurexins. The protein, called neuroligin 1 in anticipation of additional ligands for neurexins, binds only to ~-neurexins that lack an insert in the alternatively spliced sequence of the G domain, but not to I~-neurexins containing an insert. In situ hybridization reveals that the alternative splicing of neurexins in the G domain is regulated in a region-specific fashion. These observations suggest that different splice versions of neurexins have different ligands and support a role for neurexins in neuronal specificity.
Neurexins are polymorphic cell surface proteins expressed in neurons. They were discovered in the course of cloning the presynaptic receptor for ~-Iatrotoxin (Ushkaryov et al., 1992) . Three genes encoding neurexins are known (named 1,2, and 3). Each neurexin gene has two independent promoters and generates two classes of mRNAs. The longer mRNAs encode a-neurexins and the shorter mRNAs 13-neurexins. This results in the synthesis of six principal neurexin isoforms, called neurexins is to 11113, of which neurexin la corresponds to the high molecular weight component of the a-latrotoxin receptor (Ushkaryov et al., 1992 (Ushkaryov et al., , 1994 .
Neurexins are expressed at significant levels only in brain. The six isoforms are coexpressed in neurons and are distributed differentially in various brain regions. Groups of neurons exhibit different combinations of neurexins, resulting in a combinatorial specificity of neurexin expression that is generated by their cell type-specific transcription from six promoters in three genes (Uilrich et al., 1995) . Another remarkable characteristic of neurexins is their evolutionarily conserved pattern of extensive alternative splicing. ~-Neurexins share five canonical sites of alternative splicing, the last two of which are also present in 13-neurexins. At most of these splice sites, two variants are observed (negative and positive inserts). However,
Results

Purification of Neuroligin 1
To produce sufficient amounts of neurexins for biochemical studies, we constructed a baculovirus vector encoding a secretecl form of neurexin 113. The protein was truncated in the middle of the O-linked sugar region before the transmembrane region and fused to a His6sequence to facilitate purification. Recombinant neurexin 1~ was produced in Sf9 cells and purified to apparent homogeneity by a series of chromatography steps (see Experimental Procedures). Purified neurexin 113 was coupled to cyanogen bromideactivated Sepharose and used as an affinity matrix for total rat brain proteins solubilized in 3-[(3-cholamidopropyl)-dimethyl-am monio]-l-propanesulfonate (CHAPS) (Figure 1 ).
Brain proteins were loaded onto the affinity column in the presence of Ca 2÷ at physiological salt concentrations and eluted with 1 M NaCI first in the presence of Ca 2+ (Figure 1 , lanes 5-8) and then in the presence of EDTA (lanes 9 and 10). No specific binding protein was detected in the eluate containing Ca 2+. Elution with EDTA resulted in the purification of a single major protein of approximately 116 kDa, which we named neuroligin 1 (asterisk in Figure 1 ). As a control, a column containing bovine serum Neurexin 1~ and BSA were covalently coupled to cyanogen bromide-activated Sepharose. Total rat brain proteins solubilized in CHAPS (lane 1 ; L, loading material) were applied to the columns in the presence of Ca 2+, washed with loading buffer (lanes 2-4), and eluted first with 1 M NaCI and Ca 2+ (lanes 5-8) and then with 1 M NaCI and EDTA (lanes 9 and 10). Equivalent amounts of all fractions were analyzed by SDS-PAGE and Coomassie blue staining. Neuroligin 1 eluted from the neurexin 113 column by EDTA is marked by an asterisk. Numbers on the right indicate the size of molecular weight markers run in lanes labeled S. albumin (BSA) showed no bound protein (Figure 1, right) . Furthermore, application of liver proteins to the neurexin 113 column also failed to uncover specific binding proteins (data not shown). These experiments reveal the presence of a neurexin-binding protein in brain that tightly associates with neurexin 113 in the presence of Ca 2+ and is purified from total brain in a single step by affinity chromatography.
Structure of Neuroligin 1
The brain protein eluted from immobilized neurexin 113 was subjected to amino acid sequencing, cDNAs encoding neuroligin 1 were cloned based on the amino acid sequences obtained (Figure 2A ). An initiator methionine codon was identified in the nucleotide sequence as the first ATG that is not closely followed by a stop codon. Translation of the nucleotide sequence predicts synthesis of an 843 amino acid protein. Sequence analysis using hydrophobicity plots (Kyte and Doolittle, 1982) reveals two regions of high hydrophobicity: a short region at the N-terminus and a 22 amino acid sequence close to the C-terminus. The N-terminal hydrophobic sequence has the characteristics of a signal peptide (yon Heijne, 1986 ) with a predicted cleavage site after residue 44. The C-terminal hydrophobic sequence has the size and hydrophobicity of a transmembrane region.
Examination of multiple cDNA clones showed that two sequences of 27 bp and 60 bp are either present or absent, respectively ( Figure 2A ). Because these variations were found in multiple clones, it is likely that they represent alternative splicing events. Thus, neuroligin 1, like the neurexins, is subject to alternative splicing.
All of the peptide sequences obtained from purified neuroligin 1 were found in the translated cDNA sequence, suggesting that the cDNA encodes the protein purified. Purified neuroligin 1 migrates on SDS-polyacrylamide gels as a protein of approximately 116 kDa, whereas the cDNA sequence predicts synthesis of a 95 kDa protein.
The fuzzy appearance of purified neuroligin I on SDS gels (see Figure 1) suggests that it may be glycosylated. The structure of neuroligin 1 contains multiple scattered consensus sequences for N-linked glycosylation. In addition, a cluster of serine and threonine residues that may serve as O-linked sugar acceptor sites is present N-terminal to the transmembrane region ( Figure 2A ). To test whether neuroligin 1 is N-glycosylated, O-glycosylated, or both, we digested it with a series of glycohydrolases (neuraminidase, N-glycosidase F, and O-glycanase) and analyzed its size by immunoblotting. These experiments demonstrated that neuroligin I contains both N-linked and O-linked sugars, with the sugar residues accounting for the size difference between native neuroligin 1 and its primary translation product (data not shown). The O-glycosylation of neuroligin 1 may create a carbohydrate-rich domain just outside its transmembrane region, similar to O-linked glycosylation cassettes in other cell surface receptors.
The presence of a signal sequence and of a single transmembrane region in neuroligin 1 suggests that neuroligin 1 is a type 1 membrane protein with an extracellular N-terminus and an intracellular C-terminus. A domain model for neuroligin 1 is proposed in Figure 2B based on this transmembrane topology. According to this model, neuroligin 1 contains an extracellular sequence of 651 amino acids (after signal peptide cleavage and including both alternatively spliced sequences) and a cytoplasmic region of 126 amino acids. The domain model of neuroligin 1 is supported by the observed glycosylation of neuroligin 1 and the presence of an O-glycosylation cassette N-terminal to the membrane-spanning region. In addition, a cluster of positively charged amino acids flanks the transmembrane region on the intracellular side, as is typical for stop-transfer sequences (von Heijne and Gavel, 1988) . Finally, the N-terminal esterase homology domain of neuroligin 1 (see below) further supports the assignment of the N-terminus to the extracellular space.
Neuroligin 1 Has an Esteraee-like Domain
Data base searches revealed a significant homology of almost the entire extracellular domain of neuroligin 1 with members of the esterase protein family. This diverse family of proteins includes true esterases such as acetylcholinesterase and carboxylesterase, as well as nonesterase proteins such as thyroglobulin and neurotactin (de la Escalera et al., 1990; Hortsch et al., 1990; Takagi et al., 1988 ). An alignment of the neuroligin 1 sequence with sequences of selected esterase domain proteins shows that the homology of neuroligin 1 to other members of this
• NL, neuroligin; Bal, rat bile acid-activated esterase (Han et al., 1987) ; Ace, Torpedo acetylcholinesterase (Sikorac et al., 1987) ; Car, rat carboxylesterase ES-10 (Robbi et al., 1999); Thy, rat thyroglobulin (Di Lauro et al., 1985) ; Neu, Drosophila neurotactin (de la Escalera et al., 1990; Hortsch et al., 1990) . Residues identical in at least 50% of the sequences are shown on a black background. Hyphens indicate spaces. Note that the active site serine (corresponding to residue 281 in neuroflgin 1) is substituted for an inactive residue in neuroligin 1, neurotactin, and thyroglobulin. Alternatively spliced segments of neuroligin 1 are boxed.
family is uniformly distributed over the entire length of the domain ( Figure 2C ). As it is in thyroglobulin and neurotactin, the serine residue at the active site in neuroligin 1 is replaced by an inert amino acid, suggesting that neuroligin 1 is not a catalytically active esterase. Of the six disulfidebonded cysteine residues in acetylcholinesterase, four are conserved in all members and allow a tentative assignment of disulfide bonds in neuroligin 1 ( Figure 2B ). The alternatively spliced segments of neuroligin 1 map to loops in the crystal structure of acetylcholinesterase (Sussman et ai., 1991) , indicating that these sequences are accommodated in the tertiary structure of neuroligin 1 as extended surface loops. Interestingly, the longer alternatively spliced sequence contains two cysteines and may form a disulfide-bonded ring ( Figure 2B) . A quantitative assessment of the degree of relatedness of neuroligin 1 to other members of the esterase domain family reveals that it is similarly related to all members (32%-36% sequence identity), with small differences among proteins. Neurotactin is the only member of the A blot containing total RNA from the indicated rat tissues was hybridized with a uniformly labeled neuroligin 1 probe and exposed to film at -70°C for 1 hr (top). The same blot was rehybridized with GAPDH and cyclephilin probes to control for RNA loads (bottom). Numbers on the left indicated positions of molecular weight markers (in kilobases).
(B) Subcellular fractionation of brain. Crude synaptosomes were isolated by differential centrifugation (P2), lysed hypoosmotically, and separated into fractions enriched in heavy membranes (LP1), in SPMs, in synaptic vesicles (LP2), and in cytosol (LS2). Equal aliquots of each fraction were immunoblotted using antibodies against the indicated proteins. Numbers on the left indicate positions of molecular weight markers (in kilobases).
esterase family currently listed in the data bases that, in addition to neuroligin 1, contains a transmem brane region, but neuroligin is less related to neurotactin (27% identity) than to other esterase proteins. Moreover, neurotactin is a type 2 membrane protein with an N-terminal transmembrane region whereas neuroligin 1 is a type 1 membrane protein with a C-terminal transmembrane region. Together these findings suggest that neuroligin 1 is not the mammalian homolog of neurotactin.
Expression of NeuroUgin 1 in Brain
RNA blotting experiments were performed to determine the site of expression of neuroligin 1. A single hybridizing mRNA of approximately 6 kb was observed only in brain ( Figure 3A) . No signal was detected in other tissues, even after prolonged exposure. In immunoblotting experiments with proteins from a variety of tissues, neuroligin 1 could also only be detected in brain (data not shown). In situ hybridization experiments using a specific oligonucleotide complementary to the neuroligin 1 mRNA showed a neuronal pattern of expression with weak hybridization to all brain areas (data not shown).
Enrichment of Neuroligin 1 in Synaptic Plasma Membranes
Subcellular fractionation of brain demonstrated that neuroligin 1 is enriched in synaptosomes similar to the postsynaptic density protein PSD95 (P2 in Figure 3B ). Subfractionations of the synaptosomes into synaptic vesicles (LP2), cytosol (LS2), and synaptic plasma membranes (SPMs) show that neuroligin 1 also copurifies with PSD95 on SPMs. Both proteins are completely absent from synaptic vesicles. SPMs contain both pre-and postsynaptic elements and docked synaptic vesicles, resulting in the enrichment of most synaptic vesicle proteins in this fraction in addition to their presence in the synaptic vesicle fraction (except for rab3A, which dissociates probably during docking; Fischer von Mollard et al., 1991) .
Splice Site-Specific Binding of Neuroligin 1 to p-Neurexins
Neuroligin 1 was purified in a single step from total brain by affinity chromatography on immobilized neurexin 113 containing a Hiss-tagged C-terminus. To exclude potential artifacts caused by the method of immobilization of neurexin 115 or by the presence of a Hiss sequence and to examine the binding specificity of neuroligin 1 to different neurexins, we produced a series of recombinant neurexin-immunoglobulin G (IgG) fusion proteins and tested their ability to bind neuroligin 1 (Figure 4) . We produced 11 IgG fusion proteins to examine the binding specificity of neuroligin 1: one control IgG fusion protein consisting of the signal peptide of neurexin 1~ fused to IgG (Figure 4 , IGN control) and 10 neurexin-lgG fusion proteins in which the extracellular domains of ~-or 13-neurexins are fused to the Fc domain of human IgG after splice site 4 in the last G domain repeat (diagrammed in Figure 4A ). Neurexins 11~ and 215 were expressed with or without an insert in the alternatively spliced sequence 4 in the G domain (referred to as insert-negative and insertpositive 15-neurexins; IGN 115-1, 115-3, 213.3, and 213-4 in Figure 4 ) and neurexin 11113 without an insert at this site (IGN 313-1 in Figure 4 ). In addition, four different insertnegative and insert-positive neurexin l~-IgG fusion proteins were examined.
Neuroligin 1 binding to different neurexin-lgG fusion proteins was studied by testing the ability of the proteins to affinity purify neuroligin 1 from brain homogenates. Affinity chromatography on insert-negative 13-neurexins resulted in the isolation of a family of closely spaced proteins of 110-116 kDa as the only proteins purified (see Coomassie blue-stained gel in top panel of Figure 4B ). Binding of these proteins was Ca 2÷ dependent; no protein band was detected in the eluates from insert-positive 13-neurexins. Immunoblotting confirmed that neuroligin 1 was a major , and 317, without or with a splice site insert in the G domain repeat (lanes 2-6; for neurexin 36, only the variant lacking an insert was analyzed) were used as affinity matrices for protein purification from total rat brain homogenate. The top panel depicts a Coomassie blue-stained gel of the elucomponent of the eluate from all insert-negative 13-neurexins, although the eluates from the different ~-neurexins are not stained equally by neuroligin antibodies ( Figure  4B , middle). The purification of multiple protein bands that are not equally immunoreactive with neuroligin 1 antibodies indicates that there may be additional forms of neuroligin. Comparison of the Coomassie blue stain of the eluate with that of the affinity matrix ( Figure 4B , top and bottom) suggests that neuroligin 1 binding to 13-neurexins is stoichiometric. All of the binding observed is Ca 2÷ dependent (data not shown), in contrast with the binding of brain neuroligin 1 to insert-negative 13-neurexins, no binding could be detected to insert-negative or insert-positive ~-neurexins (data not shown). Together these results suggest that neuroligin 1 binds with high affinity only to 13-neurexins that lack an insert in the alternatively spliced sequence in the G domain.
Recombinant NeuroUgin 1 Reproduces the Binding Specificity of Native Neuroligin
To determine whether neuroligin 1 binds directly to ~-neurexins or requires brain-specific proteins for binding, we used transfection to express neuroligin 1 in COS cells.
A single 116 kDa immunoreactive band was detected in transfected COS cells, but not in control cells (data not shown). Membrane proteins from transfected COS ceils
were solubilized in CHAPS and chrornatographed on immobilized neurexin-lgG fusion proteins as described above. As observed for brain homogenates, recombinant neuroligin 1 only bound to insert-negative J3-neurexins but not to insert-positive l~-neurexins ( Figure 4C ). Furthermore, no binding of recombinant neuroligin 1 to J3-neurexins was detected (data not shown). Testing of multiple neuroligin 1 proteins that contain or lack inserts in the two alternatively spliced regions of neuroligin 1 showed that alternative splicing has no apparent effect on neurexin binding. These experiments confirm that we cloned a functionally active ligand for l~-neurexins that only reacts with ~-neurexins lacking an insert in the G domain splice site.
Presence of Native Neurexin-Neuroligin Complexes in Brain
Immunoprecipitations were performed to examine whether brain contains a complex of endogenous neurexins and neuroligin 1. Neurexins were immunoprecipitated from brain in the presence of Ca 2÷ using an antibody that reacts with the C-terminus of both a-and I~-neurexins. This antibody was shown previously to immunoprecipitate c~-Iatroates to demonstrate quantitative isolation of neuroligin 1 (arrows) by all three insert-negative 6-neurexins but not by insert- toxin-binding sites potently from rat brain (Hata et al., 1993a) . Immunoprecipitates were washed with high salt and eluted with EGTA. As controls, protein A beads containing no antibodies or preimmune serum were processed identically. Immunoblotting of the eluates demonstrated that neuroligin 1 could be eluted from the immunoprecipitates obtained with the neurexin antibody but not from control immunoprecipitates ( Figure 5 ). Two bands are observed similar to the purification of neuroligin 1 using neurexin-lgG fusion proteins, possibly because of proteolytic degradation or owing to the presence of multiple forms of neuroligin. Thus, native brain homogenates contain a complex between endogenous neurexins and neuroligin 1.
Primary Hippocampal Neurons Bind Recombinant p-Neurexins
To determine whether neuroligin 1 is a cell surface protein, we incubated transfected COS cells with ~-neurexin-lgG fusion proteins. Only COS cells expressing neuroligin 1 bound insert.negative neurexin 113 at 4°C and 37°C and internalized it at 37°C during a 24 hr incubation. In contrast, the control IgG fusion protein did not bind (data not shown), This suggests that neuroligin I on the cell surface can bind 13-neurexins, suggesting that developing neurons in culture may also expose binding sites. Therefore, we incubated primary hippocam pal neurons from rat embryos with an insert-negative neurexin ll3-1gG fusion protein. At 4°C, specific binding of neurexin 11~ in dotlike structures was observed, and longer incubations at 37°C resulted in their internalization ( Figure 6 ; data not shown). Binding and internalization of 13-neurexins were present all over the cell surface but concentrated on neurites.
Differential Expression of Neurexin Splice Forms in Brain
The specificity of neuroligin 1 binding to only one splice ternative splicing of neurexins in cell-cell interactions. This raises the question whether alternative splicing at the corresponding site of the neurexins is regulated. To address this, we investigated the distribution of alternative splicing of neurexin mRNAs in rat brain by in situ hybridization using specific oligonucleotides. Neurexins 1 and 2 had to be analyzed together in these experiments because their sequence similarity in this region did not allow synthesis of isoform-specific probes. The hybridization patterns of splice site-specific oligonucleotides with rat brain sections reveal major differences in the regional distributions of spliced sequences (Figure 7 ). For example, the striatum, substantia nigra, and cerebellar nuclei exhibit much higher levels of insertpositive than of insert-negative neurexin 1 and 2 mRNAs whereas the CA3 region of the hippocampus and the cere- Pictures show film autoradiograms exposed 3-6 weeks. Note the distinct differential expression of splice variants in areas such as the cerebellar nuclei (CN), the striatum (S), the substantia nigra (SN), the dentate gyrus (DG), and the CA3 region (CA3) of the hippocampal formation.
bral cortex show the opposite pattern. For neurexin 3, the most striking difference in distribution is observed in the hippocampus, where the pyramidal neurons of CA1 to CA4 have no detectable insert-positive mRNA but express high levels of insert-negative mRNA. Thus, alternative splicing at the site that regulates neuroligin 1 binding to 13-neurexins is highly regulated.
Discussion
Neurexins are neuronal cell surface proteins characterized by a high degree of polymorphism that results from an unusually diverse pattern of alternative splicing. Using affinity chromatography on immobilized neurexin 11{3, we have isolated a protein named neuroligin 1 that tightly binds to 13-neurexins but not to a-neurexins. Neuroligin 1 interacts with all three 13-neurexins, but it only binds to those 13-neurexins that lack an insert in the alternatively spliced sequence in the G domain. Cloning of neuroligin 1 revealed that it constitutes a novel type 1 membrane protein with a large extracellular domain, a single transmembrane region, and a cytoplasmic tail. Data base searches showed that neuroligin 1 belongs to a class of proteins referred to as esterase domain proteins because of their homology to esterases such as acetylcholinesterase, although neuroligin 1 lacks the active site serine residue required for catalytic activity. Thus, a ligand for !3-neurexins was discovered that only binds to one splice form of 13-neurexins and is itself an intrinsic membrane protein on the neuronal cell surface. Based on these data, we would like to propose that surface expression of neuroligin 1 and 13-neurexins on neurons leads to tight interactions between these neurons. This recognition event is dependent on the alternative splicing of the 13-neurexins in the G domain, which exhibits a distinct differential distribution in brain. (z-Neurexins do not bind, although they also contain the site of alternative splicing that regulates l~-neu rexin binding, presumably because the N-terminal sequence unique to 13-neurexins is involved in neuroligin 1 binding. Therefore, recognition among neurons mediated by the neurexin-neuroligin interaction is dependent on transcriptional regulation (expression of different 13-neurexins that are heterogeneously distributed) and regulation of alternative splicing. This demonstrates an interaction between intrinsic membrane proteins that is regulated by alternative splicing. Interestingly, agrin, a secreted protein that contains G domains, is also alternatively spliced at two positions next to or in a G domain (Rupp et al., 1991 ; Ruegg et al., 1992) . Alternative splicing of agrin regulates its biologic activity (Ruegg et al., 1992; Ferns et al., 1993) , but no splice site-specific receptor for agrin has been identified.
The model for the function of 13-neurexins and neuroligin 1 is supported by the following findings. First, neurexins and neuroligin 1 are both neuronal cell surface proteins. Second, neuroligin 1 only binds to one of two splice variants of 13-neurexins in the G domain, a domain that also serves to mediate binding to cells in other proteins (Gehlsen et al., 1992) . Third, the alternatively spliced sequence recognized by neurotogin 1 is differentially distributed in brain. Fourth, a native complex between endogenous neurexins and neuroligin 1 is present in brain. (z-and 13-neurexins are expressed in many splice variants in brain that may give rise to more than 2000 proteins (UIIrich et al., 1995) . Neuroligin 1 only binds to one splice variant of ~-neurexins that is present in only half of the 13-neurexins. Thus, neuroligin 1 is a ligand only for a small fraction of neurexins. Major additional ligands for neurexins remain to be discovered that could collaborate to determine the specifity of interactions between neurons.
The exact subcellular Iocalizations of neurexins and neuroligin 1 and the place of their interaction are unknown. It is tempting to speculate that they may mediate interactions between neurons at the synapse. This hypothesis is suggested by the localization of neurexin 1 to synapses, the homology of neuroligin 1 to synaptic acetylcholinesterase, its enrichment in SPMs together with a postsynaptic density marker, and the Ca 2+ dependence of neurexinneuroligin binding since synaptic structures are dependent on extracellular Ca 2+. It would imply that neurexins are localized to the presynaptic terminal and neuroligin 1 to the postsynaptic side and that their interaction contributes to the organization of the synapse. The regulated expression of the alternatively spliced variant of 13-neurexins that binds neuroligin 1 suggests that the 13-neurexin-neuroligin 1 interaction may stabilize subclasses of synapses. The tight interaction of neuroligin 1 with l~-neurexins could form a stable scaffold for other interactions, thereby increasing the specificity of interactions or specifying a defined sequence of interactions.
Experimental Procedures
Production of Recombinant Neurexins by Expression in Baculovirus and in COS Cells
Neurexin 115 was cloned into the baculovirus expression vector pVL1392 (Invitrogen) by fusing its extracellular domains at the Sail site (corresponding to residue 1339 in neurexin la; Ushkaryov et al., 1992 ) to a His6 sequence followed by a stop codon. Recombinant baculoviruses were produced (Summers and Smith, 1987) and used to infect Sf9 cells cultured in serum-free medium (SF900-11, GIBCO). Recombinant neurexin 19 was purified from the culture medium 72 hr after infection by precipitation with 75% ammonium sulfate, by chromatography on concanavalin A-Sepharose, and by chromatography on NF÷/NTA-agarose (Qiagen). Neurexin 113 was eluted by 0.25 M imidazole, dialyzed, and purified further by anion exchange chromatography on MonoQ and by gel filtration on Superdex-2O0, after which the protein was electrophoretically pure (yield of 10 rag/I). Purified neurexin 1~ was coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia) with 5 g of protein per liter of gel. Construction of ~-neurexin-lgG and [5-neurexin-lgG fusion protein constructs and production of protein by transfection in COS cells were performed as described by Ushkaryov et al. (1994) .
Purification of Neuroligin 1 and Protein Sequencing
Rat brains (60 g) were homogenized in 0.25 1 of buffer A (0.1 M NaCI, 4 mM KCI, 5 mM CaCI2, 2.5 mM EDTA, 20 mM NaHCO3, 20 mM Tris-HCI [pH 7.5], 0.1 g/I PMSF, 1 mg/I leupeptin, 1 mg/I pepstatin A, and 1 mg/I aprotinin). CHAPS was added to a final concentration of 2% (w/v) and dissolved under stirring at 4°C for 1 hr. Insoluble material was removed by low speed (2,000 x g) and high speed (80,000 x g) centrifugations. The supernatant (approximately 220 ml) was diluted with an equal volume of buffer A and chromatographed on the affinity columns (neurexin llB-Hise coupled to Sepharose, BSA coupled to Sepharose, and different IgG proteins attached to protein A-Sepharose) preequilibrated in buffer A containing 0.80/o CHAPS. Columns were eluted with buffer B (1 M NaCI, 4 mM KCI, 5 mM CaCI2, 2.5 mM EDTA, 20 rnM NaHCO3, 20 mM Tris-HCI [pH 7.5], 0.8% CHAPS) followed by buffer B containing 25 mM EDTA and 25 mM EGTA. Samples were analyzed by SDS-polyac rylamide gel electrophoresis (SDS-PAGE) and by silver staining, Coomassie blue staining, and immunoblotting. For amino acid sequencing, neuroligin 1 was separated on an SDS gel, blotted, and digested with trypsin (Hata et al., 1993b) . Sequences were obtained after high pressure liquid chromatography purification of tryptic fragments on an ABI amino acid sequencer.
cDNA Cloning, Construction of Expression Vectors, and COS Cell Expression of Neuroligin The longest peptide sequence from neuroligin 1 (ELN NEILVPVIQFLG-VPYAAPPT) was chosen to design short oligonucleotides complementary to its ends. Sequences, with letters in parentheses indicating redundant positions, are as follows: CGCGAGCTCAA(C,T)AA (C,T)G-A(G,A)AT(A,T,C)(T,C)T and GGGCTGCAGCNGC(A,G)TANGGNAC-NCC. The cDNA sequence encoding the peptide was cloned by PCR using single-stranded rat brain cDNA as a template and sequenced. Multiple related sequences were obtained, indicating the possibility of multiple neuroligins. An oligonucleotide was designed (CGCCCAT-GGTCAATAACGAGATACTGGGCCCGGTCGTGCAGTTCTTGG) on the basis of the PCR sequence most closely related to the peptide sequence and used in a second set of PCRs with a fourth oligonucleotide based on the peptide sequence PYKELVDQ (sequence, TGCA-
GATCTTGGTCCAC[C,T]A[G,A][T,C]TC[C,T]TT[A,G]TANGG)
. A 0.8 kb product from this PCR encoding the correct sequence was used for screening rat cDNA libraries. Of the clones isolated, 19 were characterized by DNA sequencing, and six were fully sequenced. Expression vectors were created by subcloning two cDNA clones that either contain or lack the the alternatively spliced sequences (pNLig37a and pNLig62b) into pCMV-based expression vectors and transfected into COS cells (Ushkaryov et al., 1994) .
Antibodies and ImmunoprecipitaUons
Antibodies were raised against a synthetic peptide from the C-terminus of neuroligin 1 (sequence, CHPHPHPHSHSTTRV) coupled to keyhole limpet hemocyanin (Johnston et al., 1989) . Aliquots (5 ml) of CHAPSsolubilized rat brain homogenates prepared as described above were incubated for 2 hr at 4°C with 20 ~1 of preimmune serum, anti-neurexin antibodies (Hata et al., 1993a) , or no additions. After adding 50 p~l of protein A-Sepharose (Pharmacia) preequilibrated with buffer A containing 1% CHAPS and 5 g/I BSA, samples were incubated for 14 hr. Beads were washed twice in buffer A containing 1% CHAPS and in buffer S and eluted in buffer B containing 25 mM EDTA and 25 mM EGTA. The eluate was precipitated with TCA and analyzed by SDS-• PAGE and immunoblotting.
~-Neurexin-lgG Binding to Transfected COS Cells and Primary Hippocampal Neurons
Primary hippocampal neurons were cultured on polylysine-coated coverslipe (Banker and Cowan, 1977) , Coverslips after 4-10 days in vitro were transferred to 12-well dishes, IgGs and IgG fusion proteins purified from the media of COS cells transfected with control DNA or with neurexin 1~ and control IgG fusion protein vectors were added to the culture medium. After 2 or 24 hr incubation at 4°C or 37°C, coverslips were rinsed with medium, fixed in 4% paraformaldehyde, 0.1 M phosphate buffer [pH 7.4], treated with 0.3% Triton X-100 (5 min), and blocked in 2% goat serum (1 hr). Cells were stained with a mouse monoclonal antibody against MAP2 (Sternberger)followed by fluorescein-conjugated goat anti-mouse antibodies and rhodamine-labeled goat anti-h u man IgG. Transfected COS cells were transferred to polylysine-coated coverslips 1 day after transfection, cultured for 2 days more, and then treated the same way as the hippocampal cultures,
In Situ Hybridizations
In situ hybridizations were performed (UIIrich et al., 1995) using rat brain cryostat sections and 3sS-labeled oligonucleotides of the following sequences: insert-negative neurexins 1 and 2, GAAGATTGTGAG-CTGACGCCCTGCAGGGTATCGTTCGATGAC; insert-positive neurexins 1 and 2, ACTCGACCAAGTCGATATGGAATTCGCTGTCTA-GCAATCGCCAG; insert-negative neurexin 3, GAAGATGGTT AGCT-GCCGGCCTGTAGGATAATGCTCAI-rCAC; insert-positive neurexin 3, CAGGCCGA'I-I-ATATI-IGAAGGGGAt t t tCTGtt/tACCATI-I-GG; and neuroligin 1, CTTCTGCAGGCATFCTACTAACTCTACTGTATCT-GACACA. For controls, all hybridizations were performed with a 50-to 100-fold excess of unlabeled oligonucleotide to displace specific signals, resulting in a complete abolition of signal.
Miscellaneous Procedures
Subcellular fractionation of fresh rat brains was performed as described previously (Jones and Matus, 1974) . SDS-PAGE, iromunoblotting, and silver staining were performed using standard procedures and antibodies described previously (Johnston et al., 1989; Ushkaryov et al., 1992) . RNA blots were purchased from Clontech and hybridized with uniformly labeled cDNA probes (Ushkaryov et al., 1992) .
